NCT02551263View on ClinicalTrials.gov

Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer

CompletedOBSERVATIONAL
Enrollment

201

Participants

Timeline

Start Date

July 22, 2015

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions
Breast Cancer
Interventions
DRUG

Eribulin

Eribulin 1.4 mg/m2 will be administered intravenously over 2 to 5 minutes on day 1 and 8 of every 21-day cycle, in a real-world setting.

Trial Locations (2)

650-0047

Kobe City Medical Center General Hospital, Kobe

606-8507

Kyoto University Hospital, Kyoto

All Listed Sponsors
collaborator

Kyoto Breast Cancer Research Network

OTHER

lead

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

OTHER

NCT02551263 - Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter